



Date: 04-07-2025

To
The Corporate Relation Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400001

Dear Sir / Madam,

Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018

Subject: Outcome of the Board Meeting and Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, at their meeting held on Friday, July 04, 2025, and pursuant to the recommendations of the Audit Committee, inter alia, considered and approved the following:

1. Re-appointment of Mr. T. N Raghavendra, Practicing Chartered Accountant, as an Internal Auditor of the Company for the Financial Year 2025-26, in accordance with the provisions of Section 138 of the Companies Act, 2013 read with rules made thereto;

Brief details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the aforesaid re-appointment are enclosed herewith in **Annexure A**.

2. Divestment/Sale/Disposal of entire partnership stake held in Anugraha Chemicals, a registered partnership firm (“Anugraha”), in one or more tranches.

In order to achieve sustainable long-term growth by focusing on the new venture and for further strengthening of their on-going businesses, the Board approved to sale/dispose its entire partnership stake, i.e, 66.50%, held in Anugraha to Mr. Sourabh Hadimani (“Existing Partner of Anugraha Chemicals”) or his nominee, who is not a related party of the Company, in one or more tranches. Consequently, upon completion of the said transaction, the Company shall cease to be a partner in Anugraha Chemicals.

Pursuant to the provisions of Regulations 24 & 37A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 180 (1) (a) of the Companies Act, 2013, prior approval of shareholders of the Company shall be obtained for the proposed



Pharmaids Pharmaceuticals Limited

transaction. Accordingly, the Board has decided to obtain approval of shareholders through Postal Ballot for the above said business.

Brief details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in respect of the aforesaid transaction are enclosed herewith in **Annexure B**.

3. Approved Notice to be sent to the shareholders for seeking approval for following items, through postal ballot by means of electronic voting (remote e-voting) (“Postal Ballot Notice”) in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities & Exchange Board of India.

Sl. No.	Particulars
1	To approve Material Related Party Transactions with Koye Lifesciences Private Limited (“Koye”), related party of the Company.
2	To approve Divestment/Sale/Disposal of entire partnership stake in Anugraha Chemicals, material subsidiary of the Company, in one or more tranches.

Postal Ballot Notice shall be sent to the shareholders in due course and the same shall be filed with the Stock exchange.

The Board Meeting commenced at 04:00 P.M. and concluded at 04:45 P.M.

Kindly take the same on your record and oblige.

Thanking You

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)



Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Circular.

Sl. No	Particular	Details
1	Name of the Internal Auditor	Mr. T. N Raghavendra, Practicing Chartered Accountant.
2	Reason for change viz. appointment, resignation, removal, death or otherwise;	Re-appointment as an Internal Auditor for Financial Year 2025-26
3	Date of appointment and Term of appointment	Date: July 04, 2025 For Conducting Internal Audit of the Company for the Financial Year 2025-26
4	Brief Profile	Mr. T. N Raghavendra is a Practicing Chartered Accountant and Proprietor having an experience in conducting Statutory Audits, Tax Audits, Company Audits, and VAT Audits for a diverse client comprising trading concerns, individuals, firms, companies, and charitable institutions. His office, located at 2nd Floor, Kushal Central, Opposite Krishna Theatre, M G Road, Tumkur – 572101, is renowned for its extensive network and adherence to best practices.
5	Disclosure of relationships between directors.	Not Applicable

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance officer)



Disclosures under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and SEBI Master Circular.

Sl. No	Particular	Details
	Name of the Company/Body Corporate ceased to subsidiary	Anugraha Chemicals (“Partnership Firm”)
a	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division or undertaking or subsidiary or associate company of the listed entity during the last financial year;	Anugraha Chemicals Contribution in Consolidated Revenue as on March 31, 2025: Amount: Rs.13,40,05,450/- Percentage (%): 68.91 Anugraha Chemicals Contribution in Consolidated Networth as on March 31, 2025: Amount: Rs. 3,74,15,092/- Percentage (%): 6.80
b	Date on which the agreement for sale has been entered into	The transaction is subject to approval of the shareholders through postal ballot. The Company shall execute enabling agreement which shall be subject to such approval. Final Exit agreement shall be executed upon receipt of such approval. As on date, no agreement for sale has been entered into by the Company.
c	The expected date of completion of sale/disposal	Six months from the date of receipt of shareholders’ approval
d	Consideration received from such sale/disposal	Rs. 10,50,00,000/- (Rupees Ten Crore Fifty Lakh Only) to be received from Anugraha Chemicals.
e	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof	Mr. Sourabh Hadimani, existing partner of the Anugraha Chemicals or his nominee. The proposed buyer or his nominee does not belong to the promoter/ promoter group/group companies of the Company.



Pharmaids Pharmaceuticals Limited

f	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length	The transaction will not fall within related party transactions.
g	Whether the sale, lease or disposal of the undertaking is outside Scheme of Arrangement? If yes, details of the same including compliance with regulation 37A of LODR Regulations	<p>Yes. The aforesaid transaction is not part of a Scheme of Arrangement.</p> <p>Further, the sale of partnership interest in Anugraha attract in one or more tranches, the terms of regulation 37A of the LODR Regulations, as it constitute an undertaking or substantially the whole of the undertaking for the Company under section 180 (1)(a) of the Companies Act, 2013.</p> <p>The Board of Directors has approved to obtain shareholders’ approval by means of passing special resolution under Section 180(1)(a) and 188 of the Companies Act, 2013 through postal ballot notice.</p>
h	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not Applicable

Note - The above transaction will take place after approval of shareholders by passing a Special Resolution through Postal Ballot.

For Pharmaids Pharmaceuticals Limited

Prasanna Subramanya Bhat
(Company Secretary & Compliance officer)